Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Kidney Transplant Recipients
2008-006840-20Phase 4Completed
- Sponsor
- Wyeth
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in kidney allograft rejection and chronic kidney disease (CKD) (2 arms), sponsored by Wyeth. Primary endpoints: Renal function improvement at 24 months and Safety of planned transition to sirolimus-based therapy. Started Sep 2009; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney allograft rejectionchronic kidney disease (CKD)
Beyond the preview
Go deeper on 2008-006840-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006840-20.